Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

PubMed Links for Books (Select 2823854)

1.

Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW.

J Clin Oncol. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. Epub 2012 Dec 17.

2.

Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.

Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD.

Int J Cancer. 2013 May 1;132(9):2127-33. doi: 10.1002/ijc.27909. Epub 2012 Nov 5.

PMID:
23065684
3.

Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).

Sharma A, Apostolidou S, Burnell M, Campbell S, Habib M, Gentry-Maharaj A, Amso N, Seif MW, Fletcher G, Singh N, Benjamin E, Brunell C, Turner G, Rangar R, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Fourkala EO, Ryan A, Parmar M, Jacobs I, Menon U.

Ultrasound Obstet Gynecol. 2012 Sep;40(3):338-44. doi: 10.1002/uog.12270.

4.

Ovarian cancer: etiology, risk factors, and epidemiology.

Hunn J, Rodriguez GC.

Clin Obstet Gynecol. 2012 Mar;55(1):3-23. doi: 10.1097/GRF.0b013e31824b4611. Review.

PMID:
22343225
5.

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Prat J.

Virchows Arch. 2012 Mar;460(3):237-49. doi: 10.1007/s00428-012-1203-5. Epub 2012 Feb 10. Review.

PMID:
22322322
6.

Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes.

Lim AW, Mesher D, Gentry-Maharaj A, Balogun N, Jacobs I, Menon U, Sasieni P.

J Natl Cancer Inst. 2012 Jan 18;104(2):114-24. doi: 10.1093/jnci/djr486. Epub 2012 Jan 13. Erratum in: J Natl Cancer Inst. 2013 Dec 4;105(23):1841.

7.

The epidemiology of endometrial and ovarian cancer.

Cramer DW.

Hematol Oncol Clin North Am. 2012 Feb;26(1):1-12. doi: 10.1016/j.hoc.2011.10.009. Epub 2011 Nov 25. Review.

8.

Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.

Xu JL, Commins J, Partridge E, Riley TL, Prorok PC, Johnson CC, Buys SS.

Gynecol Oncol. 2012 Apr;125(1):70-4. doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22.

9.
10.

Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.

Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC Jr.

Gynecol Oncol. 2011 Sep;122(3):548-53. doi: 10.1016/j.ygyno.2011.06.002. Epub 2011 Jun 25.

11.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.

PMID:
21642681
12.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.

Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.

13.

Results from four rounds of ovarian cancer screening in a randomized trial.

Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS; PLCO Project Team.

Obstet Gynecol. 2009 Apr;113(4):775-82. doi: 10.1097/AOG.0b013e31819cda77.

14.

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I.

Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.

15.

A randomized study of screening for ovarian cancer: a multicenter study in Japan.

Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T.

Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20. Epub 2007 Jul 21.

PMID:
17645503
16.

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK; PLCO Project Team.

Am J Obstet Gynecol. 2005 Nov;193(5):1630-9. Erratum in: Am J Obstet Gynecol. 2005 Dec;193(6):2183-4.

PMID:
16260202
17.

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.

Goff BA, Mandel LS, Melancon CH, Muntz HG.

JAMA. 2004 Jun 9;291(22):2705-12.

PMID:
15187051
18.

Screening for ovarian cancer: a pilot randomised controlled trial.

Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH.

Lancet. 1999 Apr 10;353(9160):1207-10.

PMID:
10217079
19.

Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.

Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D.

BMJ. 1993 Apr 17;306(6884):1030-4.

20.

Prospective study of serum CA-125 levels as markers of ovarian cancer.

Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW.

JAMA. 1993 Mar 3;269(9):1123-6.

PMID:
8433467
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk